Artivion (AORT) Projected to Post Quarterly Earnings on Monday

Artivion (NYSE:AORT - Get Free Report) is anticipated to release its Q1 2025 earnings data after the market closes on Monday, May 5th. Analysts expect Artivion to post earnings of $0.12 per share and revenue of $94.81 million for the quarter. Artivion has set its FY 2025 guidance at EPS.

Artivion (NYSE:AORT - Get Free Report) last posted its earnings results on Monday, February 24th. The company reported ($0.39) earnings per share (EPS) for the quarter, missing the consensus estimate of $0.12 by ($0.51). Artivion had a positive return on equity of 5.15% and a negative net margin of 0.22%. The firm had revenue of $97.31 million during the quarter, compared to the consensus estimate of $100.82 million. On average, analysts expect Artivion to post $0 EPS for the current fiscal year and $1 EPS for the next fiscal year.

Artivion Stock Up 0.1 %

Artivion stock traded up $0.03 during midday trading on Friday, hitting $23.36. 253,995 shares of the stock were exchanged, compared to its average volume of 302,567. Artivion has a 52-week low of $20.98 and a 52-week high of $32.33. The company has a quick ratio of 1.33, a current ratio of 1.88 and a debt-to-equity ratio of 0.71. The business's 50-day moving average price is $23.95 and its 200-day moving average price is $27.20. The stock has a market capitalization of $997.22 million, a price-to-earnings ratio of -1,168.00 and a beta of 1.65.

Analysts Set New Price Targets

Several equities analysts have recently issued reports on the company. Needham & Company LLC reduced their target price on Artivion from $34.00 to $32.00 and set a "buy" rating for the company in a report on Tuesday, February 25th. Stifel Nicolaus decreased their target price on Artivion from $33.00 to $30.00 and set a "buy" rating for the company in a research report on Tuesday, February 25th. Five analysts have rated the stock with a buy rating, According to MarketBeat.com, the company presently has a consensus rating of "Buy" and an average target price of $31.40.

Insider Activity

In related news, SVP Jean F. Holloway sold 5,335 shares of the company's stock in a transaction that occurred on Monday, February 24th. The shares were sold at an average price of $27.31, for a total transaction of $145,698.85. Following the sale, the senior vice president now directly owns 149,799 shares in the company, valued at approximately $4,091,010.69. This represents a 3.44 % decrease in their position. The sale was disclosed in a filing with the SEC, which can be accessed through this hyperlink. Also, insider John E. Davis sold 15,100 shares of Artivion stock in a transaction that occurred on Tuesday, March 11th. The shares were sold at an average price of $23.61, for a total transaction of $356,511.00. Following the completion of the transaction, the insider now owns 208,778 shares of the company's stock, valued at $4,929,248.58. This represents a 6.74 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders have sold 90,799 shares of company stock valued at $2,356,223 in the last 90 days. Insiders own 7.60% of the company's stock.

About Artivion

Artivion, Inc manufactures, processes, and distributes medical devices and implantable human tissues worldwide. The company provides BioGlue, a polymer consisting of bovine blood protein and an agent for cross-linking proteins for cardiac, vascular, neurologic, and pulmonary procedures; cardiac preservation services; PhotoFix, a bovine pericardial patch; and aortic arch stent grafts including E-vita Open Plus and E-vita Open Neo.